Srivichaivejvivat Public Company (VIH) Fair Value & Analysis
Healthcare · TH · Market cap 4.9B THB
Fair value as of: Jun 24, 2026
Analysis
Srivichaivejvivat Public Company (VIH) currently trades at 8.05 THB, while our model-based Fair Value estimate is 14.69 THB — implying the stock looks roughly 82.5% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
Srivichaivejvivat Public Company Limited, together with its subsidiaries, engages in the hospital business in Thailand. The company offers medical services, such as accidental and emergency center, pediatric clinic, obstetrics and gynecology center, orthopedic center and joint center, stroke system center, health checkup center, gastroenterology and hepatology clinic, internal medical clinic, cardiovascular center, vascular surgery, endoscopic surgery center, neurological and brain clinic, dental clinic, x-ray center, breast clinic, dialysis center, occupational medical clinic, women's disease laparoscopic surgery, social security clinic, physical therapy, skin and laser surgery clinic, plastic surgery clinic, kidney stones and prostate disease center, cancer clinic, radiotherapy center, child development center, sports medicine center, wellness and anti- aging health center, traditional Chinese medicine center, infertility treatment center, mother and child health center, health an…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Srivichaivejvivat Public Company (VIH) undervalued?
What is the fair value of VIH?
What is the quality score of VIH?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.